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lockade of immune-regulatory receptors, such as pro-
grammed cell death protein-1 (PD-1) and cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4) mitigates T
cell suppression, and restores T cell activation and proliferation,
thereby reinvigorating antitumor immunity1. Immune check-
point blockade (ICB) targeting PD-1 and CTLA-4 is now
implemented into the standard therapies of an increasing number
of tumor entities, resulting in durable responses and increased
survival in a substantial number of patients2,3. While efficacy in
metastatic disease to the brain indicates that the central nervous
system (CNS) is not a general barrier for ICB-mediated stimu-
lation of antitumor immunity4,5, evidence from randomized
clinical trials suggest that primary malignant brain tumors, such
as glioblastoma are largely resistant with few hypermutated
glioblastoma, representing an exception6,7. Hypermutation
in glioblastomas is not strictly associated with an increased
intratumoral T cell response8–10, indicating that hypermutation
per se is not sufficient for an effective antitumor immunity
induced by ICB. Contrariwise, durable responses may occur in
patients with glioblastoma (GBM) without hypermutation11.
Due to the overall low response rate with very few patients
responding, both the establishment of predictive biomarkers and
the identification of resistance mechanisms is challenging.
Syngeneic orthotopic glioblastoma models have been considered
insufficient models to assess interindividual heterogeneity of
immune responses. To evaluate mechanisms of response and
resistance to ICB, we made use of a syngeneic experimental
hypermutated orthotopic glioma model exceeding 100 non-
synonymous mutations per tumor exome12–14 to ensure sufficient
immune recognition of neo-epitopes.
Here, we made use of the dichotomy of response and non-
response to ICB in a hypermutated glioma model to develop a
predictive radiomic imaging signature and to uncover cellular
and molecular mechanisms of response and non-response in the
glioma immune microenvironment, providing a rationale for
targeting programmed death-ligand 1 (PD-L1)-expressing tumor-
associated macrophages to overcome resistance to ICB.
Results
Preclinical MRI-based response evaluation for GBM immu-
notherapy. Combination ICB therapy targeting PD-1 and CTLA-
4 suppressed tumor growth of established syngeneic orthotopic
mouse gliomas (Fig. 1a–d). Despite strict syngeneity of the model,
we observed a dichotomy in tumor growth upon ICB therapy in
ICB responder (R) and non-responder (NR) mice as monitored
by serial magnetic resonance imaging (MRI; Fig. 1b, d). To
evaluate the dynamics of response and resistance in individual
mice, we defined preclinical MRI response criteria based on the
established clinical RANO (response assessment in neuro-
oncology) critera15. ICB response in the preclinical model was
determined by the comparison of d13 baseline lesion volumes
(MRI1) with d26 post therapy lesion volumes (MRI3) using T2-
weighted MRI. Assessment of lesion volumes (V) and their
relative increase between d13 and d26, as well as d19 (MRI2,
during ICB therapy) and d26 strongly correlated with the
assessment of the lesion bidimensional diameter product (area)
used in RANO criteria (Supplementary Fig. 1a, b). We next aimed
at translating planumetric RANO criteria to tridimensional
(volumetric) response criteria by correcting for area–volume
divergence (Supplementary Fig. 1c). For tridimensional response
criteria, complete response (CR) was defined as relative change in
lesion volume MRI3–MRI1 (%VMRI3–MRI1) of −100%, partial
response (PR) as %VMRI3–MRI1 ≤−65.0% and/or %VMRI3–MRI2 ≤
−65.0%, stable disease (SD) as %VMRI3–MRI1 >−65.5% and <+
40%, and progressive disease (PD) as %VMRI3–MRI1 ≥+ 40%.
Lesions with an unconfirmed progression, defined by a %
VMRI3–MRI1 ≥+ 40% that showed a regression of at least −30%
between MRI2 and MRI3 (%VMRI3–MRI2) were classified as SD
(Fig. 1e, Supplementary Fig. 1c, right). Taking the rapid tumor
progression of Gl261 tumors into account, mice with CR, PR, and
SD were grouped as ICB R and mice with PD were defined as ICB
NR. Response evaluation of a dataset of 212 ICB-treated (ICB)
and 73 control-treated (C) mice revealed a response rate of
47.64% (ICB) compared to 5.48 % (C; Fig. 1f, p > 0.001).
Monotherapy with PD-1 blockade showed a reduced response
rate (33.33%, Supplementary Fig. 1d–g) compared to anti-PD-1
and anti-CTLA-1 combination therapy as previously described16.
ICB response evaluation based on MRI data translated into
a significantly enhanced survival in ICB R mice (Fig. 1g).
Mutanome analysis of ICB R and ICB NR tumors revealed no
significant difference in the number and clonality of mutations
with a sufficient number of putative neo-antigens to induce
tumor immunity (Fig. 1h–j). The mutanome of ICB R and
ICB NR tumors was heterogeneous with 23.35% of all
identified mutations enriched in ICB R tumors and 19.82% of all
identified mutations enriched in ICB NR tumors (Fig. 1j).
Although initial tumor size weakly correlated with therapy
response (Supplementary Fig. 2a), response was not restricted to
small pretreatment tumor volumes and was independent of
preexisting, environmental, and genetic factors, including housing
or gender (Supplementary Fig. 2b, c). Notably, heterogeneity
of response to ICB therapy was not restricted to experimental
gliomas but also occurred in experimental syngeneic B16 mela-
nomas (Supplementary Fig. 3a).
Radiomic evaluation of ICB response and pseudoprogression.
In serial MRI, we observed evidence of pseudoprogression, where
ICB therapy induced an initial increase of the measurable MR
lesion between MRI1 and MRI2 followed by a rapid regression
between MRI2 and MRI3 in 77.23% of ICB R mice (growth pattern
2; G2), while only 19.80% of ICB R mice showed immediate lesion
regression between MRI1 and MRI2 or response between MRI2
and MRI3 without pseudoprogression (G1; Fig. 1c; Fig. 2a).
Delayed response of ICB-treated mice with pseudoprogression (G2
growth pattern) resulted in significant bigger tumor volumes on
MRI3 compared to directly responding mice (G1 growth pattern;
Fig. 2b). However, no significant difference in response between
MRI2 and MRT3 was present between G1 and G2 ICB R (Fig. 2c),
suggesting that direct response is not a prerequisite for optimal ICB
response and methods to monitor pseudoprogression in ICB R are
relevant to distinguish pseudoprogressing ICB R from ICB NR.
To non-invasively predict treatment response (R vs. NR) and
pseudoprogression in ICB-treated mice, we implemented an
MRI-based radiomic approach. We calculated a set of 423
radiomic features from the T2-hyperintense tumor volume for
each time point and incorporated features from MRI1 and the
change in radiomic features between the MRI1 to MRI2 for
radiomic signature discovery. By constructing a gradient boost
classifier, we identified a radiomic signature that allowed to
predict treatment response with an accuracy of 82.7% (95%
confidence interval, 79.8–85.4%; sensitivity: 69.8%; and specifi-
city: 89.9%). Predictive accuracy was significantly higher as
compared to the null model (no information rate of 64.2%) (P <
0.001; Fig. 2d, e, Supplementary Fig. 3b). The top radiomic
feature for prediction of therapy failure to ICB therapy was the
shift in the volume to surface ratio between MRI1 and MRI2
(Fig. 2f). As diagnosis, tumor imaging and response monitoring
for glioblastoma patient is routinely performed with T1
−weighted contrast-enhanced MRI, response evaluation by T2-
weighted imaging was validated by simultaneous T1−weighted
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contrast-enhanced (CE) imaging. T2 and T1 CE tumor volumes
strongly correlated (R² 0.96; Supplementary Fig. 3c), and T1 CE
measurements did not provide an additional benefit for response
prediction in pseudoprogressing ICB R (G2 R; Supplementary
Fig. 3d).
Impaired antitumor T cell immunity in ICB NR mice. To
unravel mechanisms of ICB treatment failure in ICB NR mice, we
next examined intratumoral T cell infiltration and T cell
cytotoxicity in ICB NR tumors. Although T cell infiltration in ICB
NR tumors was significantly lower compared to ICB R tumors
(Fig. 3a, Supplementary Fig. 4a), no alterations in relative fre-
quencies of CD8+ and CD4+ tumor-infiltrating lymphocytes
(TILs) of ICB R compared to NR mice were observed (Supple-
mentary Fig. 4a). Antitumor TIL responses of ICB NR TILs were
diminished as TILs from ICB NR showed an impaired potency to
lyse syngeneic glioma cells ex vivo compared to ICB R and
control-treated TILs (Fig. 3b). ICB NR CD8+ TILs displayed a
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more polyclonal T cell receptor (TCRβ) repertoire compared to
ICB R CD8+ TILs, suggesting a failure of proliferation of tumor-
reactive clones in NR tumors (Fig. 3c). This was further sup-
ported by the identification of a shared CDR3 sequence motif
(alterations of 1 or less AA between ICB R mice) in the CD8 TIL
population of ICB R mice that was not present in ICB NR CD8
TILs (Supplementary Fig. 4b). Additionally, ICB R tumors were
characterized by significantly reduced frequencies of regulatory
T cells (Tregs; Fig. 3d). No significant evidence of differential PD-1
surface expression or upregulation of immunosuppressive mole-
cules (CD73 and CD38) on NR CD4+ and CD8+ TILs was
observed (Supplementary Fig. 4d, gating strategy Supplementary
Fig. 5a, c). In order to assess if responding mice developed long-
term immunity against Gl261 cells, Gl261-bearing mice were
treated with ICB as previously described, response was assessed
by MRI between d21 and d29, and mice were followed up for
57 days after tumor inoculation until lesions regressed completely
or showed stable, minimal lesion volumes. Responding mice were
rechallenged with Gl261 cells by intracranial injection into the
contralateral hemisphere at day 57 and were followed for 63 days.
Here, rechallenged R mice did not develop Gl261 tumors as
confirmed by MRI and survival analysis (Fig. 3e, f), suggesting
an efficient activation of tumor-reactive T cells and a protective
long-term immunity in ICB R mice. Strikingly, depletion of
CD8+ T cells was not sufficient to abrogate response to ICB,
while no tumor showed ICB-induced regression after depletion of
CD4+ T cells (Fig. 3g, h; Supplementary Fig. 4e-f). This suggests
an important role of effector CD4+ T cells in driving the response
to checkpoint blockade.
Suppressive myeloid cell infiltrates mediate ICB failure. Based
on the importance of CD4+ T cells for mediating response to ICB
and their close interaction with myeloid cells, we reasoned that
antitumor T cell responses are critically shaped by the intratu-
moral myeloid compartment interacting with CD4+ T cells.
Resistance to ICB therapy in other tumor types has previously
been linked to tumor-associated macrophages (TAM) and
myeloid-derived suppressor cells17,18. Therefore, we investigated
the presence and phenotype of glioma-infiltrating myeloid cells in
ICB R and NR mice. tSNE-guided (t-Distributed Stochastic
Neighbor Embedding) immune cell subset identification by
multiparameter flow cytometry analysis revealed markedly
decreased frequencies of tumor-infiltrating myeloid cell subsets,
including monocytes, monocyte-derived cells (MDCs), and
macrophages in ICB R compared with NR animals (Fig. 4a, gating
strategy Supplementary Fig. 5a-d, Supplementary Fig. 6a). Of
note, there was no evidence for enhanced apoptosis of
CD45highCD11b+ cells in ICB R tumors (Supplementary Fig. 6b,
c). Despite decreased frequencies of tumor-infiltrating myeloid
cells in ICB R tumors, we did not observe significant differences
in the frequency of circulating blood CD11b+ cells and their
expression of the chemokine receptors CCR2, CCR4, CCR5, and
CCR6 involved in myeloid cell recruitment to gliomas during ICB
therapy (d15; Supplementary Fig. 6d, e) and response establish-
ment (d21; Supplementary Fig. 6f, g). Moreover, cytokine/che-
mokine array analysis of ICB R, NR, and control-treated mice did
not reveal enhanced plasma levels of myeloid cell-attractant
chemokines and factors, such as CCL2, CCL3, CCL4, CCL5,
CCL11, CCL17, Macrophage colony-stimulating factor (M-CSF)
and granulocyte M-CSF in NR plasma during the early treatment
phase (Supplementary Fig. 6h).
Targeting of myeloid cells by CSF1R inhibition has been
investigated for the treatment of glioblastoma patients with
the aim of (1) hindering myeloid cell infiltration into the tumor
and (2) reprogramming suppressive myeloid cells to a pro-
inflammatory phenotype19,20. Here, we reasoned that CSF1R-
targeted therapy might elevate ICB response by releasing T cell
suppression by intratumoral myeloid cells. CSF1R blockade by
monoclonal antibodies increased therapy response from 33.33%
(ICB) to 54.53% (ICB+ CSF1R blockade) with only 2 out of 11
mice showing tumor progression of >40% between MRI2 and
MRI3 (compared to 6 out of 12 in the ICB cohort; Fig. 4b,
Supplementary Fig. 7a, b).
Glioma-associated myeloid cells have been reported to
suppress antitumor T cell responses and promote tumor
progression21. We hence sought to characterize the myeloid cell
phenotype, and activation in ICB R and NR tumors in more
detail. Intratumoral MDCs and macrophages from ICB R mice
expressed higher levels of major histocompatibility complex
(MHC) II, while the expression of the immunosuppressive
molecules PD-L1 and the poliovirus receptor (CD155) was
strongly reduced (Fig. 4c, Supplementary Fig. 8a, b). Expression
of PD-L2, the second ligand of PD-1, was not differentially
regulated in MDCs and macrophages in ICB R compared to NR
tumors (Supplementary Fig. 8b). PD-L1 in the tumor micro-
environment was predominantly expressed on intratumoral
monocytes, MDCs, and macrophages, while expression of PD-
L2 was less restricted and present on other immune cell subsets as
well as tumor and stroma cells (Fig. 4d). Moreover, MDCs in ICB
R tumors showed increased levels of tumor necrosis factor
(Fig. 4c, Supplementary Fig. 8a), suggesting a pro-inflammatory
phenotype. In line with these findings, NanoString gene
expression analysis of intratumoral CD45highCD11b+ cells
revealed that CD45highCD11b+ cells from ICB NR tumors
displayed an increased expression of anti-inflammatory genes
involved in inhibition of IL1b- and IL1a-mediated inflammatory
responses (Il1rn), IL4 signaling (IL4ra), and M2-associated
genes, such as PD-L1, TGFbi, and the scavenger receptor Msr1
(Fig. 4e, f). Contrary, CD45highCD11b+ cells from ICB R tumors
Fig. 1 PD-1 and CTLA-4 blockade decreases Gl261 tumor growth in ICB R mice. a–d C57Bl/6 J mice were treated with 250 µg anti-PD-1 and 100 µg anti-
CTLA-4 (ICB+) or isotype control (C) on d13, d16, and d19. Tumor growth was monitored by MRI on d13 (MRI1), d19 (MRI2), and d26 (MRI3) post
intracranial Gl261 injection (n= 19 vs. n= 7 animals). b, c Tumor growth and representative MR images of ICB+responder (R), non-responder (NR), and
control-treated (C) mice. d Response assessed by % of tumor growth between d19 and d26, and between d13 and d26 post tumor inoculation.
e, f Advanced response evaluation was performed on an extended dataset (ICB n= 212 vs. C n= 73 animals). Mice were grouped according to their
response pattern with complete response (CR): %VMRI3–MRI1 −100 %, partial response (PR): % VMRI3-MRI1≤−65.0 % or % VMRI3-MRI2≤−65.0 %, sfig
disease (SD): %VMRI3–MRI1 >−65.0% and <+ 40.0% or %VMRI3–MRI1≥+ 40.0% and %VMRI3–MRI2≤−30% and progressive disease (PD): %VMRI3–MRI1≥
+ 40.0%. e Relative increase in lesion volume MRI1–MRI3 (%VMRI3–MRI1) vs. relative increase in lesion volume MRI2–MRI3 (%VMRI3–MRI2). f Response
pattern of ICB and C mice. g Survival of ICB R and ICB NR mice (n= 6 vs. n= 10 animals). Data of two independent experiments were pooled. h Tumors of
ICB R and ICB NR mice were excised on d26 post tumor inoculation and exonic non-synonymous (n.s.) mutational load was assessed by exome sequencing
(n= 3 vs. n= 3 animals). i, j Clonality of mutations in ICB R and ICB NR tumors i and mutations predominantly enriched in ICB R or ICB NR tumors, VAF,
variant allele frequency. j Data are represented as mean ± SEM for b, h and i. Statistical significance was determined by two-tailed Student’s t-test for
b, d and h, Fisher’s exact test for f or log-rank Mantel–Cox test for g. Source data are provided as a Source Data file.
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upregulated pro-inflammatory genes known to induce Th1 T cell
responses, including the cytokine Il12 and genes involved in
MHC II presentation (H2-DMb2). As PD-L1 was differently
expressed on the majority of myeloid cell populations with the
strongest differences on intratumoral macrophages (Fig. 4c,
Supplementary Fig. 8a), we sought to investigate the impact of
PD-L1 expression on the effector functions of ICB R and NR
tumor-associated myeloid cells. Interestingly, differences in PD-
L1 expression between ICB R and NR were exclusively observed
in myeloid cells in the tumor microenvironment and not
present in the periphery (Supplementary Fig. 8c). Strikingly,
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Fig. 2 Radiomic prediction of therapy response to ICB therapy. a–c C57Bl/6 J mice were treated with 250 µg anti-PD-1 and 100 µg anti-CTLA-4 (ICB+)
and tumor growth, therapy response and pseudoprogression were evaluated by MRI before (MRI1), during (MRI2), and after ICB therapy (MRI3). a Growth
pattern analysis of ICB R (n= 101 animals). G1: %VMRI2–MRI1 < 0% and %VMRI3–MRI2 < 0%; G2: %VMRI2–MRI1 > 0% and %VMRI3–MRI2 < 0%; G3: %VMRI2–MRI1
> 0% and %VMRI3–MRI2 > 0%; and G4: %VMRI2–MRI1 < 0% and %VMRI3–MRI2 > 0%. b %VMRI3–MRI1 (left), VMRI1 (baseline tumor volume; middle), and VMRI3
(final tumor volume; right) of ICB R mice with growth pattern G1 and G2 (G1 n= 20 vs. G2 n= 78 animals). c %VMRI3–MRI2 of ICB R mice with growth
pattern G1 and G2 (G1 n= 20 vs. G2 n= 78 animals). d–f Radiomic response prediction after ICB therapy based on radiomic features of MRI1 (baseline)
and MRI2 (during ICB therapy) images (n= 148 animals). Boxplot with blocks showing the interquartile range (IQR) of data points and horizontal central
line (red dot) corresponding to the median. The superimposed violin plot visualizes the distribution of the data and its probability density. Radiomic
signature score d, heatmap of radiomic features e, and top predictive radiomic features f of R and NR tumors based on radiomic features of MRI1 and MRI2.
Data are presented as mean ± SEM for b and c. Statistical significance was determined by two-tailed Student’s t-test for b–d. Source data are provided as a
Source Data file.
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a strong negative correlation with response to ICB therapy
(Supplementary Fig. 9a). The immunosuppressive molecule PD-
L1 is known to inhibit T cell proliferation and effector function
upon binding to its ligand PD-1 on T cells1. As PD-1 was blocked
in ICB-treated mice, we investigated whether PD-L1/PD-1 signal-
ing directly impacts macrophage activation and function, such as
phagocytosis as previously proposed22,23. Here, we did not
observe an increased phagocytotic activity of tumor-associated
CD45highCD11b+ cells isolated from ICB R compared to ICB
NR mice (Supplementary Fig. 9b). Moreover, ex vivo PD-L1
inhibition during phagocytosis did not induce enhanced phago-
cytic activity of TAM (Supplementary Fig. 9b). Notably, CD11b+
PD-L1− cells in the tumor microenvironment of ICB R
mice showed increased expression of MHC II compared to NR
PD-L1− myeloid cells, suggesting enhanced antigen presentation
by this PD-L1− myeloid cell subset (Supplementary Fig. 9c). To
rule out that increased frequencies of suppressive myeloid cells in
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of treatment rather than a mechanism of ICB resistance, we
correlated MRI3 tumor volumes with frequencies of tumor-
associated CD45highCD11b+ cells and percentage of PD-L1+ cells
on tumor-associated CD45highCD11b+ cells in ICB and C-treated
mice. While MRI3 tumor volumes strongly correlated with both
factors in ICB mice, no correlation was observed in C mice
(Supplementary Fig. 10a–c, left panel). Moreover, frequencies of
tumor-associated CD45highCD11b+ cells and percentage of
PD-L1+ cells on tumor-associated CD45highCD11b+ cells were
significantly correlated with tumor growth (MRI1 to MRI3, and
MRI2 to MRI3) in ICB but not C mice (Supplementary Fig. 10a–c,
middle (MRI1 to MRI3) and right (MRI2 to MRI3) panel).
Heterogeneity of tumor volumes in C mice does not reflect a
heterogeneity in the suppressive CD11b compartment.
CD4+ TIL suppression by the PD-L1/PD-1/CD80 axis. To
address whether of PD-L1-expressing myeloid cells directly
impact T cell activation and proliferation in the tumor micro-
environment, we analyzed the ability of macrophages isolated
from ICB R, NR, and control tumors to suppress T cell pro-
liferation and effector function. Suppression of CD4+, but not
CD8+ T cell proliferation was more pronounced when T cells
were co-cultured with tumor-associated myeloid cells from ICB
NR compared to R (Fig. 5a, Supplementary Fig. 11a–c). This was
accompanied by an increased expansion of Tregs after co-culture
with tumor-associated myeloid cells from ICB NR (Supplemen-
tary Fig. 11d). Furthermore, CD4+ T cell suppression and Treg
expansion were reduced upon PD-L1 inhibition during co-culture
with ICB NR tumor-associated myeloid cells (Fig. 5a, Supple-
mentary Fig. 11c, d). As PD-1 is blocked by the ICB regimen used
here, we hypothesized that T cell suppression is established by an
alternative binding partner of PD-L1 on T cells. Interestingly,
CD80 has been proposed to act as an alternative binding partner
of PD-L1 on T cells, thereby suppressing T cell proliferation and
activation24. Indeed, we confirmed CD80 expression on CD4+
and CD8+ T cells of ICB-treated mice, with a predominant
expression in the TIL compartment (Fig. 5b, Supplementary
Fig. 11e). Moreover, CD80 expression on naive, pre-activated
T cells was induced upon co-culture with tumor-associated
myeloid cells and levels of CD80 positive CD4 T cells after co-
culture with tumor-associated myeloid cells was comparable to
levels on CD4 TILs (Fig. 5c, Supplementary Fig. 11e). To inves-
tigate if blockade of the PD-L1/CD80 interaction can restore
response to anti-PD-1+ anti-CTLA-4 therapy, PD-L1 blocking
antibodies were administered in addition to the anti-PD-1 and
anti-CTLA-4 regimen. Triple ICB resulted in a decreased tumor
growth and enhanced response (11/13 vs. 6/13) to ICB therapy
when compared with ICB targeting PD-1 and CTLA-4 only
(Fig. 5d, Supplementary Fig. 11f). To confirm these preclinical
findings, we evaluated macrophage frequencies in glioblastoma
patients from a recently published clinical trial of anti-PD-1
treatment25. From this dataset, we applied CIBERSORT analysis
of RNA sequencing data from GBM tissue of R (n= 4) and NR
(n= 5) patients before anti-PD-1 therapy. In line with our find-
ings, intratumoral M2 macrophage levels as well as myeloid cell
infiltrate levels (monocytes, M0, M1, and M2 macrophages)
showed a trend toward elevated levels in NR glioblastoma
patients before anti-PD-1 therapy (Fig. 5e), supporting the
hypothesis that suppressive myeloid cell subsets impair the
induction of antitumor T cell responses by ICB therapy. In
summary, our findings suggest a distinct set of biomarkers
associated with response to ICB in a hypermutated syngeneic
glioma model that is dominated by innate (absence of intratu-
moral macrophages and absence of PD-L1 on intratumoral
macrophages) rather than adaptive immune parameters (Fig. 5f).
Discussion
Immune checkpoint inhibitors for glioma patients are now tested
in clinical trials and first results point toward poor responses,
although neo-adjuvant ICB therapy was recently shown to pro-
mote a survival benefit in glioblastoma patients6,26,27. These
studies indicate that mechanism-driven response biomarkers and
combination strategies are required, in order to define which
patients benefit from checkpoint therapy and to simultaneously
enhance therapy response.
Preclinical models have been notoriously problematic for the
identification of biomarkers, not only as they incompletely reflect
tumor biology but also because they seemingly lack inter-
individual heterogeneity. We have uncovered and mechanistically
dissected the surprising finding that heterogeneity of response is
not only observed in humans but also in syngeneic tumor models
in inbred mice. This observation may offer the opportunity to not
only elucidate novel mechanisms of response and resistance and,
novel therapeutic targets suitable for combination therapies, but
also identify potential predictive biomarkers potentially applic-
able to patients with gliomas (Fig. 5f). We have utilized this
robust heterogeneity of response and resistance with pseudo-
progression, signifying an immune response in a syngeneic high-
mutational load experimental glioma model to establish a
radiomic-based MRI signature, predicting response with high
accuracy. This signature may be useful for future clinical trials
enriched for patients with hypermutated glioblastoma similar to
the experimental model used here. Proposed signature might
additionally be applied in combination with automated quanti-
tative tumor response assessment of MRI, using artificial net-
works that will allow for improved clinical decision making28.
The establishment and application of additional MR protocols to
Fig. 3 Impaired antitumor T cell immunity in ICB NR tumors. C57Bl/6 J mice were treated with 250 µg anti-PD-1 and 100 µg anti-CTLA-4 (ICB+ ), or
isotype control (C) on d13, d16, and d19 and tumor monitoring was performed on d13, d19, and d26 post tumor inoculation. a CD3+ cell counts per mm²
tumor area assessed by immunohistochemistry (ICB R n= 3, ICB NR n= 3 animals). b CD3+ TILs were isolated by MACS from ICB R, ICB NR, and C
tumors on d27 and incubated for 4 h with Gl261 cells ex vivo. Cytotoxicity was analyzed by LDH release relative to positive lysis control (ratio). Five
samples per group were pooled. Values are corrected for spontaneous effector and target cell LDH release. c Representative ICB R and ICB NR CD8+ TCRβ
TIL repertoire and % of ten most frequent sequences. d Flow cytometry for frequency of CD25+FOXP3+ Tregs of CD4+ TILs (ICB R n= 4, ICB NR n= 6, C
n= 4 animals). e, f C57BL/6 J mice were treated with ICB on d14, d17, and d20 after Gl261 injection and tumors were measured on d14, d21, d29, d42, and
d50. Gl261 rechallenge of ICB R was performed on d57 after first tumor injection. Tumor volumes on d14 and d21 after rechallenge e and survival f of Gl261
rechallenged ICB R and control-injected mice (n= 5 vs. n= 5 animals). g, h CD8+ or CD4+ T cells were depleted prior and during ICB using monoclonal
depletion antibodies (4 × 500 µg 2.43 or 2 × 1000 µg GK1.5). g ICB response in CD8+-depleted or naive mice (ICB+ CD8 naive n= 13, ICB+CD8 depl.
n= 13 animals) and h in CD4 depleted or naive mice (ICB+ CD4 naive n= 12, ICB+ CD4 depl. n= 12 animals). Data are represented as mean ± SEM for
a, d and e. Statistical significance was determined by one-way ANOVA with Tukey’s test for d, two-tailed Student’s t-test for a, e, g and h or log-rank
Mantel–Cox test for f. Source data are provided as a Source Data file.
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Fig. 4 Enhanced frequencies of PD-L1-expressing macrophages in ICB NR tumors. C57Bl/6 J mice were treated with 250 µg anti-PD-1 and 100 µg anti-
CTLA-4 (ICB+ ), or isotype control (C) on d13, d16, and d19 and tumors were monitored by MRI on d13, d19, and d26 post Gl261 injection.
a Multiparameter flow cytometry analysis of CNS samples from ICB R, ICB NR, and C on d27. (ICB R n= 5, ICB NR n= 5, C n= 5 animals). tSNE-guided
immune cell subset identification using tSNE composite dimensions by multiparameter flow cytometry analysis. Relative frequencies (left) and FlowSOM-
guided meta-clustering on living and single cells (right) of ICB R, NR, and C CNS tissue. b CSF1R was targeted prior and during ICB therapy using
monoclonal antibodies (AFS98; 6 × 250 µg). Response to ICB therapy in CSF1R-targeted and control mice (ICB+ n= 12, ICB+ CSF1R depleted n= 11
animals). c Multiparameter flow cytometry analysis of CNS samples from ICB R, ICB NR, and C mice on d27. (ICB R n= 5, ICB NR n= 5, C n= 5 animals).
Heatmaps showing the median expression (value range 0–1, white–red) of pro- and anti-inflammatory markers in MDCs, classical monocytes, alternative
monocytes, macrophages, and microglia clusters in ICB R, NR, and C CNS tissue. d PD-L1 and PD-L2 expression on identified CNS subsets from
stochastically selected cells from ICB R, ICB NR, and C CNS tissue. e, f Pro- and anti-inflammatory gene signature score (geometric mean of pro- and anti-
inflammatory genes) e and gene expression of pro- and anti-inflammatory genes f in tumor-associated CD45highCD11b+ cells (macrophages) from ICB R
and ICB NR assessed by NanoString analysis (ICB R n= 4, ICB NR n= 3 animals). Center line of the boxplot shows the mean and the whiskers represent
the upper and lower most quartiles. Data are represented as mean ± SEM for a. Statistical significance was determined by two-tailed Student’s t-test for
b and e. Source data are provided as a Source Data file.
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image immunotherapy-induced immune responses in the CNS
will further facilitate therapy monitoring and response evaluation.
Heterogeneity of response allowed for the precise analysis of
the glioma immune microenvironment associated with response
and resistance in this model. We identified a PD-L1+ macro-
phage subset that drives resistance to ICB by suppression of
CD4+ T cell activation and proliferation and Treg induction
(Fig. 5a, Supplementary Fig. 11c, d). PD-L1 expression of tumors
has long been believed to be the major prerequisite for efficient
PD-1 blockade. High PD-L1 expression in the initial tumor tissue
was associated with poor response to nivolumab in the Check-
Mate 143 trial (NCT02017717) for patients with recurrent glio-
blastoma6. Loss of PTEN has been associated with an increase of
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Fig. 5 TAMs establish ICB resistance through PD-L1-CD80-mediated CD4+ T cell suppression and Treg expansion. a, c Ex vivo T cell suppression by
tumor-associated myeloid cells. CD11b+ cells were purified from ICB R, ICB NR, and C tumors on d27 by MACS and co-cultured for 72 h with pre-activated
naive CD3+ splenocytes with and without 20 µgml−1 anti-PD-L1 (10 F.9G2; ICB R n= 4, ICB NR n= 4, C n= 4 animals). a CD4+ T cell proliferation after co-
culture assessed by CFSE staining. b Frequency of CD80+ cells of CD8+ (left) and CD4+ (right) TILs (ICB R n= 3, ICB NR n= 6, C n= 8 animals). c CD80
expression on pre-activated naive CD4+ and CD8+ T cells before and after co-culture with tumor-associated myeloid cells from ICB R, ICB NR, and C. d Tumor
growth (left) and response (right) of C57BL/6 J mice treated with 250 µg anti-PD-1 and 100 µg anti-CTLA-4, and as combinatory therapy with additional
200 µg anti-PD-L1 on d13, d16, and d19 post Gl261 inoculation (aPD-1+ aCTLA-4 n= 13, aPD-1+ aCTLA-4+ aPD-L1 n= 13 animals). e CIBERSORT analysis of
a GBM expression dataset of PD-1 inhibitor-treated patients before therapy (R n= 4, NR n= 5 biologically independent samples)—two-sided WRST.
f Mediators of ICB response (Z-transformed log2 fold change R/NR). Data are represented as mean ± SEM for a, b, c and e. For a, statistical significance was
determined by one-way ANOVA in combination with Dunnett’s test (CD3+ cells+ R, NR, or C CD11b+ cells vs. T cells only) and Sidak’s test for multiple
comparison (CD3+ cells+ R CD11b+ cells vs. CD3+ cells+NR CD11b+ cells) or two-tailed paired Student’s t-test (− PD-L1 vs.+ PD-L1). Statistical significance
was analyzed by one-way ANOVA with Tukey’s test for multiple comparison for b, by one-way ANOVA in combination with Dunnett’s test (CD3+ cells+ R,
NR, or C CD11b+ cells vs. T cells only) for c, by unpaired two-tailed Student’s t-test for d, and WRST with Benjamini–Hochberg correction for e. Source data are
provided as a Source Data file.
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clinical trials resistance to PD-1 inhibitors is associated with
genetic alterations in the PTEN gene25. However, PD-L1 is not
only expressed on tumor cells but also infiltrating leukocytes in
glioblastoma32–34 and PD-L1 expression on macrophages has
been associated with poor survival and resistance to immu-
notherapy for patients with glioblastoma35,36. Recent studies
highlight the impact of tumor-derived factors on PD-L1 expres-
sion on macrophages37–39. These clinical studies and our data are
in line with previous observations that macrophage infiltration
and PD-L1 expression on infiltrating macrophages are critical
determinants of resistance to ICB. It is a widely accepted view
that signaling induced by PD-1/PD-L1 interaction impairs T cell
effector function and proliferation that subsequently results in T
cell exhaustion and decreased tumor immunity1. However, the
impact of PD-1/PD-L1 binding on the phenotype, and function of
PD-L1+ antigen-presenting cells and tumor cells is still incom-
pletely understood. Here, we have shown that PD-L1 expression
on macrophages is accompanied by the expression of other
immunosuppressive molecules such as CD155 (Supplementary
Fig. 8b) and that frequency of PD-L1+ myeloid cells is negatively
correlated to therapy response to checkpoint blockade (Supple-
mentary Fig. 9a). This data is supported by evidence that suggests
an induction of a regulatory macrophage profile of PD-L1+
macrophages upon PD-L1 signaling40. Binding of PD-1 on T cells
to PD-L1 on macrophages hence decreases inflammatory med-
iators while increasing the production of anti-inflammatory
cytokines40. It remains to be investigated, if this also holds true
for the CD80/PD-L1 interaction. We further hypothesized that
PD-1/PD-L1 signaling might interfere with macrophage effector
function, such as phagocytosis. Interestingly, PD-1 expression on
TAMs has been reported to increase during tumor progression in
murine and human tumors, and to negatively correlate with
phagocytic potency against tumor cells22. In our hands, glioma-
associated macrophages did not induce phagocytosis upon PD-L1
inhibition, suggesting an alternative mechanism of immunosup-
pression by PD-L1+ macrophages. Here, we show that combi-
nation of PD-1, CTLA-4, and PD-L1 enhances response rates and
that PD-L1+ macrophages suppress T cell proliferation under
PD-1 and CTLA-4 blockade by a compensatory mechanism
through CD80 binding.
As differences in PD-L1 expression were exclusively observed
on intratumoral macrophages and were not present in the per-
iphery, additional biomarkers will be required to monitor therapy
response to ICB, especially in the context of glioblastoma patients.
These biomarkers might address soluble factors of macrophage
recruitment, polarization, and PD-L1-inducing factors in the
blood. It moreover remains to be investigated if macrophage-
mediated resistance to ICB is acquired or preexisting, as a pre-
existing mechanism might be exploited to stratify and select
patients that benefit from checkpoint blockade therapy using
tumor samples.
In conclusion, this evidence suggests an important role of
intratumoral macrophages-expressing PD-L1 and other immu-
nosuppressing molecules in the response to PD-1 and CTLA-4
blockade, thereby inhibiting the induction of proliferation and
reactivation of tumor-reactive T cells. Strategies to enhance
therapy response to ICB might thus involve the mechanism-
driven combination of ICB and targeting of TAMs.
Methods
Mice. C57Bl/6 J wild-type mice were purchased from Charles River or Janvier
Laboratories at the age of 6–8 weeks. Animal procedures were performed in the
accordance with all relevant ethical regulations for animal testing and research, and
were approved by the governmental authorities (Regional Administrative
Authority Karlsruhe, Germany). Sex- and age-matched mice were used for further
experiments. If not stated otherwise, female mice were used for the experiments.
All mice were 7–12 weeks of age at use. Mice were kept under specific-pathogen-
free (SPF) conditions at the animal facility of the DKFZ Heidelberg.
Cell culture. Gl261 cells were purchased from the National Cancer Institute.
Gl261 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10 % fetal bovine serum (FBS), 100 Uml−1 penicillin, and 100 μg
ml−1 streptomycin (Sigma-Aldrich) at 37 °C, 5% CO2. Gl261 cells were routinely
tested for viral, mycoplasma, and non-murine cell contamination by multiplex cell
contamination test (Multiplexion GmbH)41. Primary murine T cells and myeloid
cells were cultured in RPMI-1640 (Sigma-Aldrich) with 10% FBS, 100 Uml−1
penicillin, 100 μg ml−1 streptomycin, 25 mM Hepes pH 7.4, 1 mM sodium pyr-
uvate, 5 × 10−5M 2-mercaptoethanol (Sigma-Aldrich), and 2 mM L-glutamine
(Thermo Fisher) at 37 °C, 5% CO2.
Gl261 tumor cell inoculation and tumor rechallenge. A total of 1 × 105 Gl261
tumor cells were diluted in 2 μl sterile phosphate-buffered saline (PBS; Sigma-
Aldrich) and stereotactically implanted into the right hemisphere of 7–9-week-old
female C57Bl/6 J mice (coordinates: 2 mm right lateral of the bregma and 1mm
anterior to the coronal suture with an injection depth of 3 mm below the dural
surface), using a 10 μl Hamilton micro-syringe driven by a fine step stereotactic
device (Stoelting). Tumor cell inoculation was performed under anesthesia and
mice received analgesics for 2 days post operation. Mice were checked daily for
tumor-related symptoms and sacrificed when tumor burden and stop criteria were
met or mice showed signs of neurological deficit. For tumor rechallenge experi-
ments 7–9-week-old male C57Bl/6 J mice (Charles River) were intracranially
injected with 100.000 Gl261 cells and mice were treated with anti-PD-1+ anti-
CTLA-4 on day 14,17, and 20 post inoculation. Tumor growth was monitored by
MRI on day 14, 21, 29, 42, 70, and 78 post inoculation. Responding mice were
rechallenged with 1 × 105 Gl261 cells by intracranial injection into the contralateral
hemisphere on day 57 post inoculation, as described above. In addition, 1 × 105
Gl261 cells were injected into a control group of five naive, age and sex-matched
C57Bl/6 J mice. Mice were checked daily for tumor-related symptoms and sacri-
ficed when tumor burden and stop criteria were met or mice showed signs of
neurological deficit. Mice were followed for 63 days post tumor rechallenge
(120 days after the first tumor injection) and survival was analyzed by
Kaplan–Meier survival curves using log-rank Mantel–Cox test.
In vivo antibodies. For immune checkpoint therapy, 100 μg anti-CTLA-4 (9D9,
BioXCell) per mouse and 250 μg anti-PD-1 (RMP1-14, BioXCell) per mouse or
equivalent doses of isotype control antibodies (MCP-11 and 2A3, BioXCell) were
administered by intraperitoneal (i.p.) injection in 200 μl PBS on day 13, 16, and 19
after tumor inoculation. PD-L1 blockade (200 μg per mouse 10 F.9G2 or LTF-2
isotype control, BioXCell) was performed by i.p. injection in combination with
anti-PD-1 and anti-CTLA-4 therapy on day 13, 16, and 19 after tumor inoculation.
For PD-1 monotherapy, C57Bl/6 J mice were treated with 250 μg anti-PD-1 or
isotype control (C) on day 10, 13, and 16 and tumor growth was monitored by MR
imaging on day 10, 17, and 24 post intracranial Gl261 tumor injection. For CD4 T
cell blockade, 1000 μg GK1.5 or LTF-2 isotype antibody per mouse were admi-
nistered by i.p. injection on day 13 and 20 after tumor injection. CD8 T cell
blockade was performed using 500 μg anti-CD8 2.43 or LTF-2 isotype antibody per
mouse on day 13, 17, 20, and 24 after tumor inoculation. In CD4 and CD8 blocking
experiments, ICB with anti-PD-1 and anti-CTLA-4 was performed on day 15, 18,
and 21 post inoculation to allow for T cell depletion before therapy start. Efficacy of
CD4 and CD8 depletion was confirmed before and during immune checkpoint
therapy (every third day) by flow cytometry analysis of peripheral blood lym-
phocytes and by terminal flow cytometry analysis of TILs. For CSF1R blockade,
250 μg AFS98 or 2A3 isotype antibody per mouse were administered by i.p.
injection on day 11, 14, 17, 20, 23, and 25 after tumor injection. ICB with anti-PD-
1 and anti-CTLA-4 in combination with CSF1R depletion was performed on day
13, 16, and 19 post inoculation.
Survival experiments. For survival experiments, 1 × 105 Gl261 tumor cells were
implanted into the right hemisphere of 7–9-week-old female C57Bl/6 J mice as
described above. Mice were treated with anti-PD-1+ anti-CTLA-4 or isotype
control on day 13, 16, and 19 post inoculation and MRI was performed on day 13,
19, and 26 as described above. Mice were checked daily for tumor-related symp-
toms and sacrificed when tumor burden and stop criteria were met or mice showed
signs of neurological deficit. For survival data, data of two independent experi-
ments were combined.
Tumor imaging and response criteria. MRI of Gl261 tumors was performed on
day 13, 19, and 26 post tumor inoculation on a 9.4 Tesla horizontal bore small
animal NMR scanner (BioSpec 94/20 USR, Bruker BioSpin GmbH) with a four-
channel phased-array surface receiver coil. MRI was performed under inhalation
anesthesia with isoflurane. On day 13 post inoculation, mice were grouped
according to tumor size. Tumor volumes and diameters were retrieved from
standard T2-weighted sequences (TE: 33 ms; TR: 2500 ms) and tumor volume was
manually segmented in the Osirix or ITKsnap imaging software in a blinded
fashion regarding treatment condition. Treatment response was assessed analogous
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to the clinically established Immunotherapy Response Assessment in Neuro-
Oncology (iRANO) criteria15. Specifically, CR was defined as relative increase in
lesion volume MRI1–MRI3 (%VMRI3–MRI1) of −100%, PR as %VMRI3–MRI1 ≤
−65.0% and/or %VMRI3–MRI2 ≤−65.0%, SD as %VMRI3–MRI1 >−65% and <+ 40%,
and PD as %VMRI3–MRI1 ≥+ 40%. Mice with unconfirmed progression between
MRI2 and MRI3 were defined as SD, if tumors regressed at least 30% between
MRI2 and MRI3 (%VMRI3–MRI2 ≤−30.0%). Criteria for PD (NR) were met if tumor
volume increased by >=40% between MRI1 and MRI3 (thereby corresponding the
25% increase in the biperpendicular diameter mandated by the iRANO criteria,
assuming spherical configuration of the tumor). Mice with CR, PR, or SD were
defined as R mice. For validation of T2-weighted MR-based response evaluation,
T2-w imaging data of ICB- and control-treated mice was compared to T1-w
monitoring (T1-w parameters: after iv administration of 0.01 mmol Gadoteric acid:
RARE, coronal aquisition, matrix size 200 × 200, TE 6 ms, TR 1000 ms, two
averages, flip angle 90°, refocusing angle 180°, resolution; 100 μm× 100μm, slice
thickness 0.7 mm).
Radiomic signature discovery and response prediction. Radiomic analysis of
MRI data was performed with an established workflow as described previously42,43.
Briefly, radiomic features were calculated from the T2-hyperintense tumor volume
from the first MRI and the change in features between the first and second MRI for
radiomic signature discovery (Supplementary Data 1). Based on these radiomic
features (n= 423 from each time point) gradient boosting machine-learning
models were constructed to predict treatment failure at the third MRI. Model
performance was evaluated using fivefold cross validation. In more detail, lesion
volumes (MRI1 baseline lesion volumes, MRI2 during treatment lesion volumes,
and MRI3 post treatment lesion volumes) were segmented on T2-weighted MR
imaging using a region-growing segmentation algorithm implemented in ITK-
SNAP (www.itksnap.org). Radiomic features were calculated from these tumor
segmentation masks from T2-weighted MR imaging for each mouse from both
time points using the medical imaging interaction toolkit (MITK, www.mitk.org)44.
This included (i) 146 first-order features (ii) 33 volume and shape features, (iii) 200
texture features, and 44 curvature features (CF). Next, a radiomic feature set
consisting of all features from MRI1 as well as the absolute difference in each
radiomic feature between time points MRI1 and MRI2 was used as an input for
predictive modeling of treatment failure (i.e., prediction of response yes vs. no) at
MRI3 (implemented using R version 3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria) with the caret library45). All radiomic features were z-score
normalized (i.e., transformed to a mean of 0 and a standard deviation equal to 1).
Predictive modeling was performed using a gradient boosting machine-learning
algorithm that iteratively constructs an ensemble of weak decision tree learners
through boosting to form a single strong predictive model (the tuning parameters
(boosting iterations, max tree depth, shrinkage, and min. terminal node size) were
automatically optimized via resampling procedures). The performance of the
gradient boosting classifier was assessed based on a two-times repeated fivefold
cross validation resampling procedure. The held-out predictions in each of the
resampling iterations were used to calculate the accuracy, area under the receiver
operating charasteristic (ROC), sensitivity, specificity, no information rate (largest
class percentage for each molecular parameter, i.e., the prediction or accuracy by
chance), and a hypothesis test (using the binom.test function) to evaluate whether
the accuracy rate is greater than the no information rate. P < 0.05 were considered
significant.
Mutanome analysis Gl261 tumors. DNA from Gl261 tumor tissue from R and
NR mice was extracted using the INVISORB® DNA Tissue Mini Kit (STRATEC
Biomedical AG) according to the manufacturer’s instruction. RNA contamination
was eliminated by RNase digestion with 10 mgml−1 RNase at room temperature
(RT) for 5 min (Sigma-Aldrich). Exome sequencing was performed on the Illumina
NextSeq500 platform (Illumina Inc, San Diego, Calif.) using High output flow cell
(75 nt reads paired end+ 8 nt index). SureSelectXT Target Enrichment System
(Agilent Technologies) was used for library generation according to the manu-
facturer’s instructions. To convert the vendor-specific sequencing data format
generated by the Illumina NextSeq500 to a standard file format, the Illumina tool
bcl2fastq (v2.15.0.4)46 was used. To check the sequencing read quality, reports were
generated with the tool fastqc (v0.10.1)47. After quality checks the alignment was
performed with bwa mem (v0.7.5)48 and the mouse reference genome GRCm38.68.
The picard-tools (v1.105)49 were used to remove duplicates from the alignment
files. The sorting and indexing of these files was done with samtools (v0.1.19)50.
Afterward the variants were called by samtools mpileup (v0.1.19) for single-
nucleotide variants and platypus (v0.7.9.1)51 for insertions and deletions. The basic
annotations of the called variants was done with annovar (v2013-08-23)52.
B16 tumor experiments. B16 melanoma cells were kindly provided by Günther J.
Hämmerling (Division of Molecular Immunology, DKFZ Heidelberg). B16 cells
were cultured in DMEM supplemented with 10 % FBS, 100 Uml−1 penicillin, and
100 μgml−1 streptomycin (Sigma-Aldrich) at 37 °C, 5% CO2. B16 cells were rou-
tinely tested for viral, mycoplasma, and non-murine cell contamination by mul-
tiplex cell contamination test (Multiplexion GmbH)41. For B16 tumor cell
inoculation, cell suspension in PBS was mixed with an equal volume of Matrigel®
Basement Membrane Matrix (Corning®) and 5 × 104 cells in 200 μl of cell-matrix
suspension were injected subcutaneously into the right flank of C57BL/6 J mice.
Tumor growth was monitored by two-dimensional measurements using a caliper
(area: width × length). A total of 100 μg per mouse anti-CTLA-4 (9D9, BioXCell)
and 250 μg per mouse anti-PD-1 (RMP1-14, BioXCell) or equivalent doses of
isotype control antibodies (MCP-11 and 2A3, BioXCell) were i.p. injected in 200 μl
PBS on day 7, 10, and 13 after tumor inoculation. Flow cytometry analysis of
tumor-infiltrating and peripheral immune cells was performed on day 15 post
inoculation.
CD3 Immunohistochemistry. Mice were sacrificed by cardial perfusion with PBS,
excised brains were embedded in Tissue-Tek® O.C.T.TM (Sakura), and snap-
frozen in cold 2-methylbutane (Sigma-Aldrich) on dry ice. Fresh-frozen sections
were stained for CD3 with 1:100 rabbit anti-human/mouse CD3 (Dako; A 0452).
In brief, cryo-sections were fixed with 4.5% paraformaldehyde and quenching of
endogenous peroxidase was performed with 0.3% H2O2. Sections were further
washed and blocked with 4% normal goat serum in PBS at RT for 1 h. CD3 was
stained at 4 °C over night and secondary antibody incubation was performed with
biotinylated goat anti-rabbit IgG (1:200; Vector; BA-1000) in 4% normal goat
serum for 45 min at RT. After washing with PBS, the VECTASTAIN Elite ABC
HRP Kit (Vector) was applied for 30 min at RT. Slides were washed with PBS and
developed with 3,3′-Diaminobenzidine (DAB; Dako;). Reaction was stopped with
dH2O. Cryo-sections were further counterstained with hematoxylin for 3 min at
RT and developed in tap water for 10 min. Tissue sections were washed with dH2O
followed by dehydration with 70% EtOH, 96% EtOH, and 100% EtOH. Slides were
cleared thrice with Histo-Clear at RT for 3 min and mounted with histomount
medium. Images were acquired on Zeiss Cell Observer using the ZEN software.
Quantitative analysis of CD3+ T cell numbers per mm² tumor area was performed
with ImageJ.
TCR sequencing and GLIPH analysis. DNA from TIL samples was extracted by
QIAamp DNA Micro Kit (Qiagen; 56304) according to the manufacturer’s
instruction. TCRβ sequencing was performed using the TCRβ CDR3 Adaptive
Biotechnologies® sequencing technology (immunoSEQTM Kit; Adaptive
Biotechnologies; Seattle; WA)53,54. Samples were sequenced on the Illumina
NextSeq500 platform (Illumina Inc, San Diego, Calif.) using MID output flow cell
(156nt reads+ 15nt Index). Data were analyzed with the ImmunoSEQ analyzer
toolset and presented as productive amino acid sequences. Clonality was assessed
by the percentage of the top ten frequent clones of all identified productive
sequences, or productive clonality. Sequence similarity analysis was performed
using R GLIPH analysis as adapted from Glanville et al.55. TCR sequences from
healthy spleen and thymus from C57BL/6 J mice were used as reference database.
Processing of spleen, blood and tumor tissue. Spleens were excised and meshed
twice through a 70 μm cell strainer to obtain a single-cell suspension and ery-
throcytes were lysed with ACK buffer containing 150 mM NH4Cl, 10 mM KHCO3,
and 100 μM Na2EDTA. Blood samples were obtained by submandibular vein
(immune cell monitoring during experiments) or cardial puncture in deep anes-
thesia (terminal immune cell analysis) and collected in syringes or tubes coated
with 0.5 M EDTA. Erythrocytes were lysed with ACK buffer and cells were washed
twice and further processed for flow cytometry analysis. For isolation of TILs, mice
were cardially perfused in deep anesthesia. For Gl261 tumors, the right hemisphere
was excised and the cerebellum removed. For B16 tumors, flank tumors were
excised. B16 tumors and Gl261-bearing hemispheres were mechanically dissected
and enzymatically digested in HBSS (Sigma-Aldrich, 11088866001) supplemented
with 50 μg ml−1 Liberase DL (Roche) under slow rotation at 37 °C for 30 min. Cells
were subsequently meshed through a 100 μm and 70 μm cell strainer, stained, and
analyzed by flow cytometry. For Gl261 cell suspensions, cells were purified using
myelin removal beads II (Miltenyi Biotec; 130-096) according to the manu-
facturer’s instruction.
Flow cytometry. For intracellular cytokine staining, cells were incubated with 5 μg
ml−1 Brefeldin A (Sigma-Aldrich) for 5 h at 37 °C, 5% CO2 to allow for intracel-
lular enrichment of cytokines. Brain tumor and spleen cell suspensions were
blocked with anti-CD16/CD32 (eBioscience; 93; 14-0161) and extracellular targets
were stained at 4 °C for 30 min (Supplementary Data 2). Intracellular antigens were
fixed, permeabilized, and stained using the FOXP3/transcription factor staining
buffer set (eBioscience; 00-5523) and the antibodies listed in Supplementary
Data 2. Staining of intracellular targets was performed for 45 min at 4 °C. Stained
lymphocytes were analyzed on FACS Canto II (BD Biosciences; Germany) or on
Attune NxT (Thermo Fisher; Germany). FlowJo V9 or V10 were used for data
analysis. Multiparameter FACS data were generated on a FACSSymphony (BD
Biosciences) using the antibodies described in Supplementary Data 2. Data were
compensated, exported (FlowJo V10), uploaded, and normalized using Cyt3
(Matlab_R2018b). The new generated FCS files were uploaded in Rstudio (Version
1.1.463). tSNE (displaying stochastically selected events from all different condi-
tions) and FlowSOM (events from each condition) were performed as described by
Brumelman et al.56.
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Ex vivo phagocytosis. For isolation of CD11b+ cells of Gl261 tumors from ICB R,
ICB NR, and C mice, myelin was removed of tumor single-cell suspension with
myelin removal beads II (Miltenyi Biotec; 130-096) according to the manu-
facturer’s instruction. Subsequently, CD11b+ cells were purified using MagniSort™
Mouse CD11b Positive Selection Kit (eBioscience; 8802-6860-74). Ex vivo pha-
gocytosis of CD11b+ cells was assessed as previously described22. In brief, CD11b+
cells were plated onto ultra-low attachment 96-well plates (Corning) and incubated
at 37 °C, 5% CO2 for 20 min to allow for cell resting. CD11b+ cells were subse-
quently cultured at 37 °C, 5% CO2 for 2 h with pHrodo™-red Staphylococcus aureus
BioParticles (Thermo Fisher) according to the manufacturer’s instruction. Pha-
gocytosis was assessed by flow cytometry analysis for pHrodo-red+ cells of mac-
rophages (CD45highCD11b+ cells) and microglia (CD45lowCD11b+ cells). PD-L1
was blocked during incubation with pHrodo™-red S. aureus BioParticles with 20 μg
ml−1 anti-PD-L1 (10 F.9G2; BioXCell).
Apoptosis of intratumoral macrophages. Macrophages (CD45highCD11b+) of
ICB R and ICB NR were stained with annexin V-FITC (BioVision, 1:100) and
DAPI (1:250, Invitrogen, Carlsbad, USA) in Annexin V binding buffer
(eBioscience, Germany) at RT for 15 min, and analyzed using BD-FACS Canto II.
Early apoptosis was defined by single annexin V positivity. Late apoptosis was
defined as annexin V and DAPI double positivity.
Blood immune cell monitoring. Blood samples of ICB-treated mice were collected
on day 15 and 21 after Gl261 inoculation using submandibular vein puncture and
collected in tubes coated with 0.5 M EDTA. Erythrocytes were lysed with ACK
buffer containing 150 mM NH4Cl, 10 mM KHCO3, and 100 μM Na2EDTA. Cells
were washed twice with PBS and further processed for flow cytometry analysis.
Plasma cytokine array. Blood samples were collected by submandibular vein
puncture and plasma was obtained by centrifugation at 2000×g, RT for 10 min.
Plasma cytokine analysis was performed with pooled plasma samples at equal
ratios for five mice per group according to the manufacturer’s instructions
(Proteome Profiler™ Array Mouse Cytokine Array Panel A; R&D Systems;
ARY006). Samples were measured on the ChemiDocTM MP Blot reader system
(BioRad; Hercules, Calif.). ImageJ 1.48 and the Gilles Carpentier’s Protein Array
Analyzer for ImageJ toolset were used for data analysis.
Ex vivo and in vitro T cell suppression. For ex vivo and in vitro T cell suppression
assays, T cells were purified from spleens of naive C57BL/6 J mice using the Mag-
niSort™ Mouse T cell Enrichment Kit (eBioscience; 8802-6820), labeled with 5 μM
carboxyfluorescein succinimidyl ester (CFSE; Thermo Fisher; C34570) and pre-
activated prior to myeloid cell co-culture with plate-bound 0.1 μgml−1 anti-CD3
(145-2C11; eBioscience;) and 1 μgml−1 anti-CD28 (37.51; Biolegend) at 37 °C, 5%
CO2 for 16–18 h. Ex vivo T cell suppression assay with tumor-associated myeloid
cells was adapted from De Henau et al.18. In brief, Gl261-associated myeloid cells
were isolated of from ICB R, ICB NR, and C mice. To this end, single-cell sus-
pensions of tumor-bearing hemispheres were subjected to myelin removal (Myelin
removal beads II; Miltenyi Biotec; 130-096) and CD11b+ cells were purified by
MACS using the MagniSort™ Mouse CD11b Positive Selection Kit (eBioscience;
8802-6860). Gl261-associated CD11b+ cells were co-cultured with pre-activated
T cells at a ratio of 1:1 (2.5 × 104 CD3+T cells and 2.5 × 104 CD11b+ myeloid cells)
in murine T cell proliferation medium at 37 °C, 5% CO2 for 72 h. T cell proliferation
was examined by CFSE mean fluorescence intensity of living CD3+ CD8+ and living
CD3+ CD4+ T cells, and percentage of cells per cell division.
Ex vivo TIL cytotoxicity. For ex vivo cytotoxicity analysis of ICB R, ICB NR, and C
Gl261 TILs, a lactate dehydrogenase (LDH) release assay was applied (Promega;
G1780). A total of 5 × 103 Gl261 cells were seeded onto 96-well flat bottom plates
and incubated at 37 °C, 5% CO2 over night to allow for tumor cell adherence. For
isolation and purification of TILs from ICB R, ICB NR, and C-treated Gl261
tumors on day 27 post inoculation, tumor-bearing hemispheres were processed to
single-cell suspensions, and TILs were purified with myelin removal beads II
(Miltenyi Biotec; 130-096) and MagniSort™ Mouse CD3 Positive Selection Kit
(eBioscience; 8802-6840) according to the manufacturer’s instruction. Purified TILs
were co-cultured with Gl261 cells at a ratio of 10:1 (5 × 104 CD3+T− 5 × 103
Gl261 cells) at 37 °C, 5% CO2 for 4 h. A total of 4–5 ICB R, ICB NR, and C TIL
samples per group were pooled for cytotoxicity analysis. LDH release of TIL-
mediated Gl261 killing was assessed with the CytoTox 96® Non-Radioactive
Cytotoxicity Kit (Promega) according to the manufacturer’s instruction and OD
was measured on a iMarkTM Microplate reader (BioRad; Hercules, Calif.) at
490 nm. Values were corrected for spontaneous effector and target cell LDH release
and cell culture medium background. Data are represented as tumor cell lysis
relative to positive Gl261 lysis control.
NanoString analysis and inflammatory gene signatures. RNA from FACS
sorted macrophages (CD45highCD11b+) of Gl261 tumors of ICB R and ICB NR
mice was extracted using the PicoPureTM RNA Isolation Kit (Arcturus; KIT0202)
and gene expression analysis was performed using the nCounter Mouse
Immunology Panel (NanoString; XT-CSO-MIM1-12) with the nCounter Nano-
String™ technology (NanoString Technologies; Seattle, WA)57. RNA input per
sample was 25 ng. Data analysis were performed by nSolver 3.0. Marker for pro-
and anti-inflammatory gene signatures were selected according to previously
described marker. Gene signature scores were calculated as geometric mean of each
gene expression. Controls and low count genes were removed from the NanoString
count matrix, followed by a scalar normalization and variance modeling58,59.
Differential gene expression analysis was performed by an eBayes adjusted mod-
erated t-statistic linear regression model60. Pro- and anti-inflammatory metagene
signatures were generated from previously reported markers (Supplementary
Table 1) and the geometric mean was estimated in each sample for the different
signatures.
CIBERSORT analysis human glioblastoma. CIBERSORT analysis was applied to
expression data of pre-ICB (pembrolizumab/nivolumab) GBM tissue from Zhao
et al.25. Expression data from GBM samples that were obtained more than
6.5 months prior to the first ICB therapy (pembrolizumab/nivolumab) were
excluded. Response classification of patients was adapted from Zhao et al.25. In
detail, response criteria were met when samples after PD-1 inhibitor therapy
showed signs of pseudoprogression (inflammatory response with very few or no
tumor cells detectable) or stable or continually shrinking tumor lesions over a
minimum of 6 months as detected by MRI25. RNAseq *.fastq files for selected
patients were downloaded from the ENA using the Aspera Connect client. Reads
were aligned to the human genome (GRCh38) using STAR (2.7.0c), and a gene
expression matrix (as TPM) was generated using RSEM. The gene expression
matrix was analyzed by CIBERSORT using the LM22 signature gene file of 22
immune cell types61. Immune cell subtype proportions were compared using
Wilcoxon rank-sum test (WRST) and false discovery rate adjustment was per-
formed by Benjamini and Hochberg correction.
Immunogram ICB response. Fold changes (R/NR) of response features were log2
transformed and z transformation for all features was applied. Data are presented
as a radar chart.
Statistics. Data are represented as individual values or as mean ± SEM. Group
sizes (n) and applied statistical tests are indicated in figure legends. Significance was
assessed by either unpaired t-test analysis, paired t-test analysis,or one-way analysis
of variance (ANOVA) analysis with Tukey, Dunnett or Sidak post hoc testing as
indicated in figure legends. Spearman correlation was applied for all correlation
analysis and the Kaplan–Meier method was used to examine survival differences.
Statistics were calculated using GraphPad Prism 7.0.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-seq data that support the findings of this study has been deposited in the GEO
repository (GSE129877) and will be made available prior to publication. All additional
data sets generated or analyzed during this study are included in this published article
and supplementary information files. Data underlying CIBERSORT analysis was
published by Zhao J et al.25. (Nat. Med., 2019) and was accessed via the GEO repository
(GSE121810). The source data underlying Figs. 1b–j, 2a–f, 3a–h, 4a–c, 4e, f, 5a–f, and
Supplementary Figs. 1a–g, 2a–c, 3a, 3c, d, 4a, 4c–f, 6a–g, 7a, b, 8a–c, 9a–c, 10a–d, and
11b–f are provided as a Source Data file.
Code availability
The full codes of all scripts are available on reasonable request. For further information
on software package versions please refer to the Nature Research Reporting Summary
linked to this article.
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